MCID: PTT008
MIFTS: 46

Pituitary Carcinoma

Categories: Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Pituitary Carcinoma

MalaCards integrated aliases for Pituitary Carcinoma:

Name: Pituitary Carcinoma 12 53 59 15 73
Malignant Neoplasm of Pituitary Gland 73
Carcinoma of the Pituitary Gland 12
Pituitary Cancer 53

Characteristics:

Orphanet epidemiological data:

59
pituitary carcinoma
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:4916
MeSH 44 D010911
NCIt 50 C4536
SNOMED-CT 68 128665000 254955001
Orphanet 59 ORPHA300385
UMLS via Orphanet 74 C0346300
ICD10 via Orphanet 34 C75.1
ICD10 33 C75.1

Summaries for Pituitary Carcinoma

MalaCards based summary : Pituitary Carcinoma, also known as malignant neoplasm of pituitary gland, is related to hormone producing pituitary cancer and prolactin producing pituitary tumor. An important gene associated with Pituitary Carcinoma is MEG3 (Maternally Expressed 3
All normal human pituitary cell types express MEG3. However,loss of MEG3 expression occurs only in nonfunctioning pituitary adenomas of a gonadotroph origin. All other pituitary tumor phenotypes examined express MEG3. Hypermethylation of the IG-DMR at the DLK1/MEG3 locus is present in nonfunctioning pituitary adenomas.
Dysfunction Pattern: Regulation [down-regulated]), and among its related pathways/superpathways are Peptide ligand-binding receptors and Glucocorticoid receptor regulatory network. The drugs nivolumab and Lapatinib have been mentioned in the context of this disorder. Affiliated tissues include pituitary, spinal cord and liver, and related phenotypes are pituitary carcinoma and prolactin excess

Related Diseases for Pituitary Carcinoma

Diseases related to Pituitary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 hormone producing pituitary cancer 33.3 SST SSTR2
2 prolactin producing pituitary tumor 31.9 PRL SST
3 pituitary tumors 29.8 POMC PRL SST
4 functioning pituitary adenoma 29.3 POMC PRL SST
5 hypopituitarism 29.1 CRH POMC PRL
6 adenoma 28.9 POMC PRL SST SSTR2
7 acromegaly 28.4 POMC PRL SST SSTR2
8 bronchus adenoma 10.6 POMC SST
9 acidophil adenoma 10.6 POMC SST
10 acute thyroiditis 10.5 CHGA POMC
11 gastrointestinal neuroendocrine benign tumor 10.5 CHGA SST
12 adenoma of the pancreas 10.5 CHGA SST
13 gastric neuroendocrine neoplasm 10.5 CHGA SST
14 gastrointestinal neuroendocrine tumor 10.5 CHGA SST
15 syndrome of inappropriate antidiuretic hormone 10.5 CHGA POMC
16 endocrine pancreas disease 10.5 POMC SST
17 glucagonoma 10.5 CHGA SST
18 cervix small cell carcinoma 10.5 CHGA POMC
19 hyperinsulinemic hypoglycemia, familial, 2 10.5 CHGA SST
20 adenohypophysitis 10.5 POMC PRL
21 vipoma 10.5 CHGA SST
22 pancreatoblastoma 10.5 CHGA SST
23 pancreas disease 10.4 POMC SST
24 pituitary apoplexy 10.4 POMC PRL
25 somatostatinoma 10.4 CHGA SST
26 sella turcica neoplasm 10.4 POMC PRL
27 tuberculum sellae meningioma 10.4 POMC PRL
28 acth deficiency, isolated 10.4 CRH POMC
29 duodenal gastrinoma 10.4 CHGA SST
30 carcinoid syndrome 10.4 CHGA SST
31 empty sella syndrome 10.4 POMC PRL
32 hypoadrenalism 10.4 CRH POMC
33 zollinger-ellison syndrome 10.4 CHGA SST
34 tsh producing pituitary tumor 10.4 PRL SST
35 hypothyroidism, congenital, nongoitrous, 4 10.4 POMC PRL
36 fasting hypoglycemia 10.4 CRH POMC
37 pituitary adenoma 1, multiple types 10.4 PRL SST
38 gastrinoma 10.4 CHGA SST
39 central nervous system organ benign neoplasm 10.4 POMC PRL
40 adrenal cortical hypofunction 10.4 CRH POMC
41 islet cell tumor 10.4 CHGA SST
42 diabetes insipidus, neurohypophyseal 10.4 POMC PRL
43 withdrawal disorder 10.4 CRH POMC
44 sex differentiation disease 10.4 POMC PRL
45 persistent fetal circulation syndrome 10.4 CRH POMC
46 serotonin syndrome 10.4 CHGA SST
47 chromophobe adenoma 10.3 POMC PRL
48 primary pigmented nodular adrenocortical disease 10.3 CHGA POMC
49 endogenous depression 10.3 CRH POMC
50 hypoadrenocorticism, familial 10.3 CRH POMC

Graphical network of the top 20 diseases related to Pituitary Carcinoma:



Diseases related to Pituitary Carcinoma

Symptoms & Phenotypes for Pituitary Carcinoma

Human phenotypes related to Pituitary Carcinoma:

59 32 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pituitary carcinoma 59 32 obligate (100%) Obligate (100%) HP:0011763
2 prolactin excess 59 32 hallmark (90%) Very frequent (99-80%) HP:0000870
3 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
4 increased circulating acth level 59 32 hallmark (90%) Very frequent (99-80%) HP:0003154
5 pituitary prolactin cell adenoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0006767
6 pituitary corticotropic cell adenoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0008291
7 malignant neoplasm of the central nervous system 59 32 hallmark (90%) Very frequent (99-80%) HP:0100836
8 progressive visual field defects 59 32 frequent (33%) Frequent (79-30%) HP:0007987
9 enlarged pituitary gland 59 32 frequent (33%) Frequent (79-30%) HP:0012505
10 hypopituitarism 59 32 frequent (33%) Frequent (79-30%) HP:0040075
11 hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000365
12 growth hormone excess 59 32 occasional (7.5%) Occasional (29-5%) HP:0000845
13 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
14 pituitary growth hormone cell adenoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0011760
15 spinal cord lesion 59 32 occasional (7.5%) Occasional (29-5%) HP:0100561
16 diabetes insipidus 59 32 very rare (1%) Very rare (<4-1%) HP:0000873
17 pituitary gonadotropic cell adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0011759
18 pituitary thyrotropic cell adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0011762
19 mildly reduced visual acuity 59 Frequent (79-30%)
20 hemianopsia 59 Frequent (79-30%)
21 hyperpituitarism 59 Occasional (29-5%)
22 abnormality of central motor function 59 Occasional (29-5%)
23 reduced visual acuity 32 frequent (33%) HP:0007663
24 hemianopia 32 frequent (33%) HP:0012377

MGI Mouse Phenotypes related to Pituitary Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 CHGA CRH POMC SST

Drugs & Therapeutics for Pituitary Carcinoma

Drugs for Pituitary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
nivolumab Approved Phase 2 946414-94-4
2
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
3 Antibodies Phase 2
4 Immunoglobulins Phase 2
5 Antibodies, Monoclonal Phase 2
6 Protein Kinase Inhibitors Phase 2
7
Doxorubicin Approved, Investigational 23214-92-8 31703
8
Ifosfamide Approved 3778-73-2 3690
9
Vincristine Approved, Investigational 2068-78-2, 57-22-7 5978
10
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
11
Dactinomycin Approved, Investigational 50-76-0 2019 457193
12
Doxil Approved June 1999 31703
13
Isophosphamide mustard 0

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
2 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
3 Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) Completed NCT01903967
4 PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon Recruiting NCT02854228
5 International PPB Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158

Search NIH Clinical Center for Pituitary Carcinoma

Genetic Tests for Pituitary Carcinoma

Anatomical Context for Pituitary Carcinoma

MalaCards organs/tissues related to Pituitary Carcinoma:

41
Pituitary, Spinal Cord, Liver, Lymph Node, Thyroid, Lung, Bone

Publications for Pituitary Carcinoma

Articles related to Pituitary Carcinoma:

(show top 50) (show all 74)
# Title Authors Year
1
Prolactin Secreting Pituitary Carcinoma with Extracranial Spread Presenting with Pathological Fracture of Femur. ( 29456370 )
2018
2
Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. ( 29404894 )
2018
3
Neuro-Ophthalmic Manifestations of Pituitary Carcinoma. ( 29315125 )
2018
4
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). ( 29299820 )
2018
5
Combined modalities of surgery, radiotherapy, radiosurgery and chemotherapy for invasive pituitary carcinoma. ( 29525560 )
2018
6
Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. ( 29928263 )
2018
7
A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. ( 28586933 )
2017
8
Pituitary Carcinoma in a Patient with an SDHB Mutation. ( 28284009 )
2017
9
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma. ( 29137963 )
2017
10
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. ( 28432119 )
2017
11
Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide. ( 29256415 )
2017
12
Cytomorphology of metastatic pituitary carcinoma to the bone. ( 28267302 )
2017
13
Seeding of a Pituitary Adenoma or Atypical Pituitary Carcinoma? ( 28589060 )
2017
14
Metastatic Pituitary Carcinoma to Cervical Lymph Node: Diagnosis by Fine Needle Aspiration and Review of the Literature. ( 28399532 )
2017
15
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. ( 28291643 )
2017
16
Meningeal dissemination of a pituitary carcinoma to the cauda equina in a dog. ( 28761190 )
2017
17
Pituitary carcinoma: A case report and discussion of potential value of combined use of Ga-68 DOTATATE and F-18 FDG PET/CT scan to better choose therapy. ( 28840066 )
2017
18
Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease. ( 28420444 )
2017
19
Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. ( 28667593 )
2017
20
Corticotroph pituitary carcinoma in a patient with Lynch syndrome (LS) and pituitary tumors in a nationwide LS cohort. ( 28938458 )
2017
21
Response of silent corticotroph pituitary carcinoma to chemotherapy: case report. ( 27150544 )
2016
22
Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions. ( 27157283 )
2016
23
Genetic aspects of pituitary carcinoma: A systematic review. ( 27893664 )
2016
24
Secreting Follicle-Stimulating Hormone Pituitary Carcinoma with Cervical Metastasis. ( 27449685 )
2016
25
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. ( 27106209 )
2016
26
Temozolomide therapy: Focus on patients with pituitary carcinoma. ( 27365946 )
2016
27
Pituitary carcinoma with intraspinal metastasis: report of two cases and review of the literature. ( 26464743 )
2015
28
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. ( 25646794 )
2015
29
Progression of an Invasive ACTH Pituitary Macroadenoma with Cushing's Disease to Pituitary Carcinoma. ( 26366311 )
2015
30
MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. ( 25862551 )
2015
31
Diagnosis and Treatment of Pituitary Carcinoma. ( 26564466 )
2015
32
A case report of feline pituitary carcinoma with hypercortisolism. ( 24025433 )
2014
33
The Use of 68Ga DOTATATE PET/CT for Diagnostic Assessment and Monitoring of 177Lu DOTATATE Therapy in Pituitary Carcinoma. ( 25275413 )
2014
34
Pituitary carcinoma with endolymphatic sac metastasis. ( 23645293 )
2014
35
Invasive adenoma and pituitary carcinoma: a SEER database analysis. ( 24526366 )
2014
36
Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery. ( 24272034 )
2014
37
Drop metastasis of adrenocorticotropic hormone-producing pituitary carcinoma to the cauda equina. ( 25346823 )
2014
38
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma. ( 24823463 )
2014
39
Improvement in Diagnosis of Metastatic Pituitary Carcinoma by 68Ga DOTATATE PET/CT. ( 24873798 )
2014
40
Lesions of the petrous ridge: metastatic pituitary carcinoma with discussion of differential diagnosis. ( 24622018 )
2014
41
Tumor-to-tumor metastasis from pituitary carcinoma to radiation-induced meningioma. ( 22989053 )
2013
42
DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. ( 23365123 )
2013
43
Pituitary carcinoma in situ. ( 23425649 )
2013
44
Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. ( 23955641 )
2013
45
Pituitary carcinoma: a devastating disease in need of an earlier diagnosis and of effective therapies. ( 22120355 )
2013
46
Long-term follow-up of growth hormone-producing pituitary carcinoma with multiple spinal metastases following multiple surgeries: case report. ( 24077272 )
2013
47
Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. ( 24455332 )
2013
48
The significance of MEN1 mutations in pituitary carcinomas. ( 23905891 )
2013
49
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( 22520146 )
2012
50
What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? ( 23422771 )
2012

Variations for Pituitary Carcinoma

Expression for Pituitary Carcinoma

Search GEO for disease gene expression data for Pituitary Carcinoma.

Pathways for Pituitary Carcinoma

GO Terms for Pituitary Carcinoma

Cellular components related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 CHGA CRH POMC PRL SST
2 extracellular space GO:0005615 9.02 CHGA CRH POMC PRL SST

Biological processes related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.43 POMC PRL SST
2 G-protein coupled receptor signaling pathway GO:0007186 9.26 CRH POMC SST SSTR2
3 regulation of blood pressure GO:0008217 9.16 CHGA POMC
4 hormone-mediated apoptotic signaling pathway GO:0008628 8.62 CRH SST

Molecular functions related to Pituitary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CRH POMC
2 hormone activity GO:0005179 8.92 CRH POMC PRL SST

Sources for Pituitary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....